**Supplementary material**

**Table S1.** Univariate Analysis of Demographic, Clinical Characteristics and Outcomes of the Study Population According to Hospital of Recruitment

Recruitment Hospital

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Characteristics HC FAA IJC *P* Value

 n= 34 n= 25

Age, median (IQR) 50 (34 – 65) 60 (44 – 68) 0.13

Male gender, n (%) 18 (52.9) 8 (32) 0.11

Surgical patients, n (%) 21 (61.8) 21 (84) 0.06

Infection source, n (%)

 Pneumonia 15 (44.1) 11 (44) 0.90

 Abdomen 11 (32.4) 13 (52) 0.13

 Soft tissue 4 (11.8) 1 (4) 0.29

 Urinary tract 3 (8.8) 0 (0) 0.13

 Other 1 (2.9) 0 (0) 0.39

Diabetes, n (%) 8 (23.5) 4 (16) 0.48

Acute kidney injury, n (%) 20 (58.8) 11 (44) 0.26

Baseline creatinine, mg/dL 1 (0.6-1.6) 0.9 (0.7-1.5) 0.32

ARDS, n (%) 13 (38.2) 8 (32) 0.62

APACHE II score (SD) 22 ± 5.6 20 ± 6 0.34

SOFA score (SD) 11 ± 2.6 10 ± 3 0.22

Vasopressin use, n (%) 11 (32.4) 5 (20) 0.29

Maximum NE dose (mcg/kg/min) 0.31 (0.20-0.40) 0.27 (0.18-0.33) 0.07

Hydrocortisone dose (mg/kg/day) 2.71 ± 0.28 2.65 ± 0.31 0.44

NE to hydrocortisone (h) 14 (8-29) 8 (5-19) 0.09

Time to shock reversal, h 90 (52-127) 57 (46-96) 0.11

Shock relapse, n (%) 7 (36.8) 4 (19) 0.21

Hydrocortisone tapered, n (%) 12 (54.5) 11 (55) 0.97

Diuretic use, n (%) 17 (50) 13 (52) 0.88

New onset hypernatremia, n (%) 25 (73.5) 10 (40) 0.01

New onset hypokalemia, n (%) 17 (50) 13 (52) 0.88

New onset hyperglycemia, n (%) 25 (73.5) 17 (68) 0.13

Superinfection, n (%) 3 (8.8) 5 (20) 0.21

Wound dehiscence, n (%) 2 (5.9) 3 (12) 0.40

UGIB, n (%) 0 (0) 1 (4) 0.24

ICU-AW, n (%) 11 (32.4) 6 (24) 0.48

Vasopressor-free days 2 (0-4) 3 (2-5) 0.06

ICU LOS 8.5 (5-14) 9 (5-12) 0.79

30-day mortality, n (%) 18 (52) 7 (28) 0.07

HC FAA: Hospital Civil Fray Antonio Alcalde; IJC: Instituto Jalisciense de Cancerología; APACHE II: Acute Physiology and Chronic Health Evaluation; ARDS: Acute Respiratory Distress Syndrome; ICU-AW: Intensive care unit- acquired weakness; ICU LOS: Intensive care unit length of stay; IQR: interquartile range; NE: Norepinephrine; SOFA: Sequential Organ Failure Assessment; UGIB: Upper gastrointestinal bleeding.

**Figure S1.** Flowchart of the study

